Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CAD | P27708 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292935 | 0.84 | HCAR2 (0.36) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| SCHEMBL28292971 | 0.83 | — | — | |
| SCHEMBL28294538 | 0.82 | TSHR (0.41) | ALOX15ALDH1A1LMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL10636646 | 0.80 | — | — | |
| SCHEMBL28292928 | 0.79 | TSHR (0.37) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| SCHEMBL303947 | 0.79 | — | — | |
| SCHEMBL409419 | 0.78 | — | — | |
| SCHEMBL28294537 | 0.78 | NOS1 (0.36) | ALOX15ALDH1A1LMNAHSD17B10GAA | |
| SCHEMBL4321838 | 0.77 | — | — | |
| SCHEMBL5419183 | 0.76 | ALOX15 (0.42) | ALOX15ALDH1A1LMNAHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-115322250-A | Synthesis method of semaglutide | 南京汉欣医药科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-109651286-A | A kind of highly selective 4-(4- aminophenyl) morpholine -3- ketone synthetic method | 新发药业有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-108586377-B | A kind of preparation method of 3- morpholone | 上海科利生物医药有限公司 | 2019-04-05 | — | — | CN | disclosed |
| CN-108586377-A | A kind of preparation method of 3- morpholones | 上海科利生物医药有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-3377113-A2 | COMPOSITIONS AND METHOD FOR THE TREATMENT AND DETECTION OF COLON CANCER | Synergy Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| CN-102026666-B | Formulation of insulinotropic peptide conjugates | CHANGSHAN CONJUCHEM BIOTECHNOLOGIES HEBEI INC | 2013-10-16 | — | — | CN | disclosed |
| CN-102026666-A | Formulation of insulinotropic peptide conjugates | CONJUCHEM BIOTECHNOLOGIES INC | 2011-04-20 | — | — | CN | disclosed |
| US-20090088378-A1 | LONG LASTING INHIBITORS OF VIRAL INFECTION | CONJUCHEM BIOTECHNOLOGIES, INC. (CA) | 2009-04-02 | — | — | US | disclosed |
| WO-2008144590-A2 | LONG LASTING MODIFIED ANTIFUSOGENIC PEPTIDE FOR PREVENTING HIV INFECTION | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2008-11-27 | — | — | WO | disclosed |
| CN-1191273-C | Long lasting insulinotropic peptides | CONJUCHEM INC (CA) | 2005-03-02 | — | — | CN | disclosed |
| CN-1350548-A | Long lasting insulinotropic peptides | CONJUCHEM INC (CA) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088378-A1 | LONG LASTING INHIBITORS OF VIRAL INFECTION | VIP, NECTIN4, ST14 | ALOX15 3144/4885ALDH1A1 4635/4885LMNA 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.